Toralizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD40 ligand |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| KEGG | |
| Chemical and physical data | |
| Molar mass | 148,426 g/mol |
  (what is this?) (verify) | |
Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]
In Phase II clinical trials regarding multiple sclerosis and Crohn's disease, thromboembolisms occurred in at least three patients. A causal connection could not be proven, but since the same adverse effects were seen in trials with a similar antibody (hu5C8), the trials were halted.[2]
The drug was developed by IDEC Pharmaceuticals Corporation.
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Toralizumab, American Medical Association.
- ↑ Luebke, Robert W; Robert V House; Ian Kimber (2007). Immunotoxicology and immunopharmacology. Target Organ Toxicology Series (3 ed.). Boca Raton, Florida: CRC Press, Taylor & Francis Group. p. 131. ISBN 0-8493-3790-9.